GlassScriptPhysician profile
Brittany A Morgan
NPI 1366076150
$1,250.75
in general payments reported to CMS, 2019-2025
20 companies · $758 in 2025
The $758 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $56.05 · 2022: $123 · 2023: $94.93 · 2024: $219 · 2025: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,071.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $418.17 | 2024-2025 | Caplyta |
| Abbvie INC. | $152.62 | 2025 | |
| Vanda Pharmaceuticals INC. | $121.03 | 2025 | Fanapt, Hetlioz |
| Novartis Pharmaceuticals Corporation | $91.21 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $58.99 | 2022-2025 | |
| Lilly USA, LLC | $49.62 | 2023-2025 | Mounjaro, Jardiance, Trulicity |
| Genentech USA, INC. | $46.10 | 2021-2024 | Tecentriq |
| Otsuka America Pharmaceutical, INC. | $45.75 | 2025 | Rexulti |
| Kyowa Kirin, INC. | $39.32 | 2025 | |
| Amgen INC. | $34.13 | 2022-2024 | Otezla, Repatha |
| Acadia Pharmaceuticals INC | $32.35 | 2023-2024 | Nuplazid |
| Alkermes, INC. | $29.69 | 2025 | Aristada, Lybalvi |
| Dexcom, INC. | $22.55 | 2023 | Dexcom G6 Transmitter |
| Verona Pharma, INC. | $21.81 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $20.08 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $17.00 | 2025 | Immunocap |
| Astellas Pharma US INC | $14.43 | 2023 | Veozah |
| Almatica Pharma LLC | $13.45 | 2024 | Loreev Xr |
| Mylan Specialty L.P. | $11.30 | 2021 | |
| Sumitomo Pharma America, INC. | $11.15 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.